Allegro

Vicken Karageozian, MD

Show Description +

Vicken Karageozian, MD, President and Chief Medical Officer, Allegro, provides an update on the company's lead investigational drug, Luminate (ALG-1001), for the treatment of diabetic macular edema (DME) as the company prepares to enter phase 3 clinical trials.

Posted: 7/23/2018

Keywords:

ALG-1001 (Luminate; Allegro)

Up Next

Name: Allegro
Uploaded: 2018-07-23T15:19:00+00:00
Description: Vicken Karageozian, MD, President and Chief Medical Officer, Allegro, provides an update on the company's lead investigational drug, Luminate (ALG-1001), for the treatment of diabetic macular edema (DME) as the company prepares to enter phase 3 clinical trials.